ImpediMed kicks off SOZO commercial sales in Europe and Australia

Company News

by Jessica Amir

ImpediMed Limited (ASX:IPD) has commenced its first commercial sales for its SOZO platform in Europe and Australia, with shipments now underway.

The medical technology company’s digital and wellness device is used to manage and monitor a person’s fluid status, body composition and hydration levels in a clinical and home setting.

ImpediMed says its first customers to use SOZOhub are large hospitals, that connect devices to measure fluid and body indicators.

The company says soon after receiving the CE Marking its sales kicked off, while the launch of SOZO and its new software will allow the company to expand its commercial launch in the coming months, and ultimately prepare for the introduction into the US, later this year.

Shares in ImpediMed Limited (ASX:IPD) are trading 7.33 per cent higher to 80.5 cents.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.